Sara R. Fagerlie, PhD, CHCP

📢 Introducing Cancer Conference Hub Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more. 👉 Explore the hub here: bsky.app/profile/did:...

postMONARCH findings presented at #ESMO26 suggest Verzenio + Faslodex may benefit people with advanced HR+ #breastcancer after CDK4/6 inhibitor treatment. Median overall survival was 32 vs. 24.6 months (not statistically significant). Progression-free survival also improved. https://bit.ly/4ewhPCh

New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without the cancer growing. Read more: https://bit.ly/4ewhPCh #BreastCancer #BreastCancerResearch #InsightsbyESMO #Metavivor

At #ESMO26: In an analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab vs nivolumab alone in patients with melanoma, high baseline levels of LAG3hi CD8+ T cells were associated with improved response in the combination arm

Today I had the honor to discuss two important abstracts of novel treatment approaches for patients with #HCC across different stages and settings at #ESMO26. Not yet in clinical practice, but clinically relevant results. #ESMOAmbassadors @myesmo.bsky.social

#RandySweis showing data from EV-SG-zim in 1st line met #urothelialcancer — small sample size but high ORR 81% including 3 pts w CRs. Pushing depth of response for met UC. @oncoalert #ESMO26 @myESMO

Interesting ctDNA analysis from #EV304/B15 trial — ctDNA (+) groups w poor prognosis but EV-pembro works regardless of ctDNA status @myESMO #ESMO26 @oncoalert

EileenO’Reilly presents AMPLIFY-7P randomized phase 2 study of adjuvant camupepimut in patients with resected #KRAS-mutant #PDAC at #ESMO26 #ESMOAmbassadors @myesmo.bsky.social

Zev Wainberg presents subgroup analyses from phase 3 RASolute 302 study of #daraxonrasib in patients with previously treated metastatic #PDAC at #ESMO26 #ESMOAmbassadors @myesmo.bsky.social

@tonichoueiri with med onc pearls for neoantigen mRNA vaccines. The future is happening now — esp w readout of INTERPATH-001 trial this #ESMO26 @myESMO @oncoalert

🚨 The daily OncoAlert Newsletter is LIVE from Madrid 🇪🇸 #ESMO26 REGISTER for Free 👉 buff.ly/N5gYtAc Day One #ESMO26 is in: 📌 NATALEE 6-yr OS 📌 PANKU-Breast01 + Lancet pub 📌 KEYNOTE-866 & ENERGIZE, both negative in MIBC 📌 HERIZON-GEA-01 3-yr OS For colleagues… by colleagues 🤝

#ESMO26: Phase II data suggest selected patients with localised gastro-oesophageal adenocarcinoma (#GEA) may benefit from a dostarlimab watch-and-wait strategy that can achieve good responses without surgery 🔗 https://ow.ly/Mu2w50ZZiKG #InsightsbyESMO #GICancers

#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by Peter Dubsky. #InsightsbyESMO ➡️ https://ow.ly/SZoK50ZZXMf

Students Turn to Private Lenders After Trump’s Clampdown on Federal Loans www.wsj.com/personal-fin...

Precision oncology🎯 is evolving—but how do we distinguish a promising molecular target🧬 from one supported by evidence strong enough to guide treatment? www.sciencedirect.com/science/arti... The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2)

Dostarlimab FDA-approved for Stage II/III locally advanced MSI-H/dMMR rectal cancer #Medsky #oncsky www.fda.gov/drugs/resour...

🚨 Top Ten by OncoAlert : #ESMO26 GI Cancer🧬 Our faculty picked the GI abstracts from Madrid 👇 🔹 Colorectal: AZUR-1, CheckMate 8HW, TRIDENTE 🔹 Esophagogastric: HERIZON-GEA-01, KEYNOTE-975, DEWI, G-HOPE-001 🔹 Biliary: HARMONi-GI1, ACTICCA-1, OPTIMUM 🔹 Pancreatic: RASolute 302, AMPLIFY-7P

OncoAlert 4Sight, (Made from #ESMO26 Abstracts) Final Analysis of the GIM3 FATA Trial: Treatment Schedule and Three Aromatase Inhibitors in Postmenopausal HR+ Early Breast Cancer 🔬 Randomized trial (n=3697): 5 years of anastrozole, exemestane or letrozole, upfront or after 2 years of tamoxifen.

🫁 #ESMO26 Lung Cancer: the 10 abstracts our faculty say you need to know Big themes: ADCs in EGFR-mutant and first-line disease, MET after osimertinib, next-gen KRAS G12C, and how long immunotherapy should last. #LungCancer #LCSM #NSCLC #SCLC Which one are you most curious about?

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 First-Line Pembrolizumab + Lenvatinib + Belzutifan or MK-1308A + Lenvatinib in Advanced RCC: The Randomized Open-Label Phase 3 LITESPARK-012 Study

OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%: PERSEE Phase 3 Trial (GFPC 01-2020)

"By banning abortion, Idaho has become a more dangerous place to give birth." 170 obstetricians for 1 million ppl; No OBs in 22 of 44 counties. Women facing life-threatening complications are loaded into a helicopter and flown out of state for treatment. www.nytimes.com/2026/10/20/m...

AACI will honor Dr. Lucile L. Adams-Campbell with the 2026 Cancer Health Equity Award on October 26 in Chicago, recognizing her pioneering work in community-based participatory research. Learn more: aaci-cancer.cventevents.com/event/2026-a... #AACI2026 #HealthEquity

ABC News examines how disruptions to the CDC's Division of Blood Disorders and Public Health Genomics are affecting efforts to support people living with sickle cell disease. Watch the segment: https://ow.ly/yYsl50ZXZMO #Fight4Hematology

Very sad. I had the privilege of working with Dr Shroff on several education programs and she was one of the best.

Very sad news..

“I think all roads lead to MYC; however hard you try to ignore it, it’s there.” Maybe after successfully targeting KRAS anything is possible. www.nytimes.com/2026/10/02/s...

"Optogenetics is a powerful basic research tool that gives scientists a way to deftly probe living brain cells to search for the root causes of complex behaviors and devastating diseases." www.nytimes.com/2026/10/05/h...

This is a frightening time. "Paxton has also implicated[the American Academy of Pediatrics]in the alleged conspiracy...of protecting children from polio, measles, meningitis and more than a dozen other dangerous and sometimes life-threatening diseases" www.nytimes.com/2026/10/05/h...

Iron deficiency is common, affecting an estimated 1 in 3 adults in the U.S. ASH’s new guidance on diagnosing iron deficiency aims to help clinicians catch more cases earlier, so that patients can be connected to the care they need. Read the article now: https://ow.ly/OhAE50ZTUYZ

We not only need to treat infections in T-cell redirecting therapy recipients, but also identify high-risk patients, their risk timing, & employ risk-adapt approaches, Paula Rodriguez-Otero, MD, PhD, said. #IMS26

When you see improvement in overall survival with primary IVIG prophylaxis, besides reduced infection risk, this is a strategy we should adopt for T-cell redirecting therapy recipients --- Noopur Raje, MD #IMS26

Iberdomide-Dara-dex was the first approval in myeloma based on MRD-neg CR. Sagar Lonial, MD, who presented data from ph3 EXCALIBER-RRMM trial that supported the approval, said this combination is a new std of care in RRMM. #IMS26

📣 #ESMO26: The late-breaking abstract lineup is taking shape! Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect. 🔗 https://ow.ly/6Res50ZQ82a

Excited to hear @nikhilmunshi.bsky.social discuss the concept of cure in myeloma! #IMS2026

A cure for myeloma, defined. Long considered incurable, myeloma now has a consensus standard: five years off treatment with no detectable disease. “We are no longer debating whether cure is possible,” said Dr. Nikhil Munshi at #IMS26. Read more → https://ow.ly/GNG850ZQvKo

So much important information in this survey. "When the world doesn’t invest in women’s health, that dramatically impacts how they can show up at work, at home, and in their communities" #womenshealth www.pivotal.com/articles/gal...

The US National Science Foundation (NSF) is changing how it funds research grants — and how it decides which ones to fund — to better align with White House priorities, according to a letter released on 10 September. go.nature.com/4iXOjZI

Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. Full phase 3 TAISHAN-302 trial results: https://nej.md/4xKtvcF #WCLC26

$480K for daraxonrasib adds to the growing cost of cancer care, a"CAR-T therapy now goes for $600K...[another CART] is listed at $550K. A daily pill for gastrointestinal cancer has a sticker price of $520K a year. A twice-daily pill for leukemia? It’s $430K a year" www.nytimes.com/2026/08/31/b...

Heather Ranels, MA, MS, CHCP, FACEHP, offers a practical framework for selecting credible sources and for using and vetting AI outputs in the context of CPD professionals. almanac.acehp.org/Education/Ed...

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA12.04 — A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821)

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented Next week OA14.05 — Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC (HARMONi): Updated Overall Survival Analysis ✅ OS benefit durable and consistent across regions, no new safety signals

The OncoAlert #WCLC26 🇰🇷 Top 10 Deep Dive! Abstract to be presented MO15.02 A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Ooops

To address new work requirements, "state Medicaid agencies have been exploring technological solutions to automate redeterminations at scale...6 agencies have decided to use AI tools so far and 21 states are considering use of them." What could go wrong? www.cancercommunicator.com/JAMA_AI_Medi...

He’s right.

This story is more about healthcare than the headline suggests-a hospital in RI is being forced to turn over all medical records of children who received gender affirming care. What are they planning to do with that info and who will they go after next? Gift article www.nytimes.com/2026/08/30/u...

Visit 🔗 https://pancan.org/news/fda-approves-rasonque-daraxonrasib/ to learn more about RASONQUE™, including what this FDA approval means, the survival benefit for people with pancreatic cancer, potential side effects, insurance coverage and how PanCAN Patient Services can help. 💜

Thank you to The New York Times for including PanCAN Chief Scientific and Medical Officer Dr. Anna Berkenblit’s perspective on what this approval means for patients and the pancreatic cancer community. 💊 https://www.nytimes.com/2026/08/26/science/pancreatic-cancer-daraxonrasib-approval.html